CTLA4 and neoplasm: Additionally, there is a high level of immune cell infiltration in the anti-PD-1 + TIGIT-treated tumour tissue sections with a decreased level of PD-L1 expression when compared to anti-PD-1 + CTLA-4-treated or PBS control-treated tumour tissue sections (Fig. 6 a,b).